Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Ulcerative colitis
Economic impact of diagnostic testing
3 evidence topics · 3 sources
Cost-effectiveness of fecal calprotectin screening before endoscopy for suspected inflammatory bowel disease in the United States
“We constructed a decision analytic tree to compare the cost-effectiveness of measuring FC before endoscopy examination with that of direct endoscopic evaluation alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults, FC screening saved $417/patient but delayed diagnosis for 2.2/32 patients with IBD, among 100 screened patients. In children, FC screening saved $300/patient but delayed diagnosis for 4.8/61 patients with IBD, among 100 screened patients. If endoscopic biopsy analysis remained the standard for diagnosis, direct endoscopic evaluation would cost an additional $18,955 in adults and $6250 in children to avoid 1 false negative result from FC screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pre-test probabilities for IBD of ≤75% in adults and ≤65% in children made FC screening cost-effective, but cost ineffective if the probabilities were ≥85% and ≥78% in adults and children, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adopting a third-party payer perspective, only direct costs were considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote